general
Amplia gets nod for new cancer drug trial ahead of US push
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
Reported by The Age
Read the complete report at The Age ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
4 reports · 4 sources
The AgeAmplia gets nod for new cancer drug trial ahead of US pushSydney Morning HeraldAmplia gets nod for new cancer drug trial ahead of US pushThe AgeAmplia gets nod for new cancer drug trial ahead of US pushSydney Morning HeraldAmplia gets nod for new cancer drug trial ahead of US push3 recorded states
Signal first indexedP1 · 99% quality · 3 sources
Corroboration 3→4 sourcesP1 · 99% quality · 4 sources
Corroboration 4→3 sourcesP1 · 99% quality · 3 sources